Efficacy and Safety of Tirzepatide for Treatment of Overweight or Obesity. A Systematic Review and Meta-analysis
Int J Obes (Lond). 2023. DOI: 10.1038/s41366-023-01321-5
This systematic review and meta-analysis aimed to assess the efficacy and safety of tirzepatide for weight loss in patients with overweight or obesity.
Across 7 trials involving 5,800 patients (with or without T2D), 78.2%, 55.6% and 32.3% achieved ≥5%, ≥10% and ≥15% weight loss, respectively, with tirzepatide (pooled doses, 5–15 mg). Tirzepatide 5 mg demonstrated weight loss superiority relative to placebo (mean difference: −12.47 kg, 95% CI −13.94 kg to −11.00 kg) and semaglutide (mean difference: −1.90 kg, 95% CI −2.97 kg to −0.83 kg), with dose-dependent increases for 10 mg and 15 mg doses. There was increased odds of experiencing gastrointestinal AEs with tirzepatide compared to placebo, but no significant difference with semaglutide.
The authors concluded that tirzepatide has significant potential as a weight-loss drug in patients with overweight and obesity.
Keywords:
